Adverse reactions of antidepressants in elderly patients

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 20, 1999, Pages 4-8

  Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZATROPINE; BENZATROPINE MESILATE; FLUOXETINE; NEFAZODONE; NORTRIPTYLINE; OXYBUTYNIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGE; ANTICHOLINERGIC EFFECT; CAREGIVER; DEPRESSION; DISEASE SEVERITY; DOSE CALCULATION; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC CARE; HIP FRACTURE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ACCIDENTAL FALLS; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BASAL GANGLIA DISEASES; CLINICAL TRIALS; COMORBIDITY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; GUIDELINES; HIP FRACTURES; HUMANS; HYPOTENSION, ORTHOSTATIC; INAPPROPRIATE ADH SYNDROME; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032833203     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging 1992;2:356-367
2. Pollock BG. Issues in psychotropic drug development for the elderly. In: Bergener M, Brocklehurst JC, Finkel SI, eds. Aging Health and Healing. New York, NY: Springer Publishing; 1995:235-242
3. Pollock BG, Mulsant BH, Nebes RD, et al. Serum anticholinergicity in older patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998;155:1110-1112
4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262:914-919
5. National Institutes of Health Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA 1992;268:1018-1024
6. Benrimoj SI, Langford JH, Bowden MG, et al. Switching drug availability from prescription only to over-the-counter status: are elderly patients at increased risk? Drugs Aging 1995;7:255-265
7. Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995;70:685-693
8. Abrams WB, Beers MH. Clinical pharmacology in an aging population. Clin Pharmacol Ther 1998;63:281-284
9. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292-296
10. Foglia JP, Pollock BG. Medication compliance in the elderly. Essential Psychopharmacol 1997;1:243-253
11. Salzman C, Schneider LS, Lebowitz B. Antidepressant treatment of very old patients. Geriatr Psychiatry 1993;1:21
12. Mulsant BH, Pollock BG, Rosen J. Newer antidepressants and antipsychotics in geriatric psychiatry. Nurs Home Med 1997;5:240-248
13. Menting JE, Honig A, Verhey FR, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 1996;11:165-175
14. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-2032
15. Pollock BG, Perel JM. Tricyclic antidepressants: contemporary issues for therapeutic practice. Can J Psychiatry 1989;34:609-617
16. Pollock BG. Drug interactions. In: Nelson JC, ed. Geriatric Psychopharmacology. New York, NY: Marcel Dekker; 1997:43-60
17. Sweet RA, Pollock BG, Wright B, et al. Single and multiple dose bupropion pharmacokinetics in elderly patients with depression. J Clin Pharmacol 1995;35:876-884
18. Ray WA, Griffin MR, Schaffner W. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-369
19. Ruthazer R, Lipsitz LA. Antidepressants and falls among elderly people in long-term care. Am J Public Health 1993;83:746-769
20. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-1307
21. Laghrissi-Thode F, Pollock BG, Miller MC, et al. Comparative effects of sertraline and nortriptyline on body sway in elderly depressed patients. Am J Geriatr Psychiatry 1995;3:217-228
22. Laghrissi-Thode F, Pollock BG, Miller MC, et al. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacol Bull 1995;31:659-663
23. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-579
24. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294
25. Scott MA, Shelton PS, Gattis W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy 1996;16:352-365
26. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-636
27. Pollock BG, Everett G, Perel J. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacol 1992;6: 1-10
28. DeVane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995;10:S185-S193
29. Steur E. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213
30. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-282
31. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454
32. Blennow K, Wallin A, Gottfries CG, et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992;13:107-113
33. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995;15:821-829
34. Lipinski JF Jr, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50: 339-342
35. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995;152:122-125
36. Settle EC Jr. Akathisia and sertraline [letter]. J Clin Psychiatry 1993;54:321
37. Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects [letter]. Am J Psychiatry 1994;151:288
38. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
39. Mammo DC, Sweet RA, Mulsant BH, et al. The effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: a prospective doubleblind study in depressed elderly patients. Presented at the 12th annual meeting of the American Association for Geriatric Psychiatry; March 14-17, 1999; New Orleans, La
40. John L, Perreault MM, Tao T, et al. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 1997;29:287-289
41. Masood GR, Karki SD, Patterson WR. Hyponatremia with venlafaxine. Ann Pharmacother 1998;32:49-51
42. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 1997;12:61-63
43. Ranieri P, Franzoni S, Rozzini R, et al. Venlafaxine-induced reset osmostat syndrome: case of a 79-year-old depressed woman. J Geriatr Psychiatry Neurol 1997;10:75-78
44. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1996;155:519-527
45. Sharma H, Pompei P. Antidepressant-induced hyponatremia in the aged: avoidance and management strategies. Drugs Aging 1996;8:430-435
46. Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacotherapy 1997;31:108-109
47. Druckenbrod R, Mulsant BH. Fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. J Geriatr Psychiatry Neurol 1994;7: 255-258